News & Resources
The record behind SurVaxM.
Peer-reviewed publications, trial data, press coverage and corporate materials, maintained here as the current reference for clinicians, partners and media.
Press Releases
Company announcements.
Press Release
Read →
MimiVax Announces Data Cutoff for Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
Press Release
Read →
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
Press Release
Read →
MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment
Press Release
Read →
US FDA Awards Supplemental Orphan Drug Designation to SurVaxM to Now Include Treatment of Malignant Glioma
Press Release
Read →
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Resources
Publications, coverage and company materials.
Data
Read →
Final data from the Phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma
Looking for trial data
The full pipeline has phase-by-phase status.
For where each program stands today, the Pipeline page is the fuller reference.